Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems

TH Baryakova, BH Pogostin, R Langer… - Nature Reviews Drug …, 2023 - nature.com
Poor medication adherence is a pervasive issue with considerable health and
socioeconomic consequences. Although the underlying reasons are generally understood …

Covalent inhibitors: a rational approach to drug discovery

F Sutanto, M Konstantinidou, A Dömling - RSC medicinal chemistry, 2020 - pubs.rsc.org
Covalent inhibitors are recognized as an important component in drug discovery and
therapeutics. Since the first appearance of covalent inhibitors in the late 18th century, the …

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase …

KB Gordon, P Foley, JG Krueger, A Pinter, K Reich… - The Lancet, 2021 - thelancet.com
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F in addition to IL-17A. This study investigated the efficacy and safety of bimekizumab …

[HTML][HTML] Phage therapy in the resistance era: where do we stand and where are we going?

T Luong, AC Salabarria, DR Roach - Clinical therapeutics, 2020 - Elsevier
Purpose Widespread antibiotic-resistant bacteria are threatening the arsenal of existing
antibiotics. Not only are antibiotics less likely to be effective today, but their extensive use …

Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors

WH Polonsky, RR Henry - Patient preference and adherence, 2016 - Taylor & Francis
At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control
(HbA1c< 7%). One of the major contributing factors is poor medication adherence. Poor …

AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis

CW Ko, S Singh, JD Feuerstein, C Falck-Ytter… - …, 2019 - gastrojournal.org
(AGA) on the management of mild-to-moderate ulcerative colitis (UC). The guideline was
developed by the AGA Institute's Clinical Guidelines Committee and approved by the AGA …

[HTML][HTML] La adherencia al tratamiento en las enfermedades crónicas

LE Ramos Morales - Revista cubana de angiología y cirugía vascular, 2015 - scielo.sld.cu
Introducción: la falta de adherencia al tratamiento en el contexto de las enfermedades
crónicas es considerada como un grave problema de salud. Objetivo: examinar los …

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

P Vermersch, A Czlonkowska… - Multiple Sclerosis …, 2014 - journals.sagepub.com
Background: In previous studies, teriflunomide significantly reduced the annualised relapse
rate (ARR) and disability progression. Objective: This phase 3, rater-blinded study …

Medication non-adherence among elderly patients newly discharged and receiving polypharmacy

L Pasina, AL Brucato, C Falcone, E Cucchi, A Bresciani… - Drugs & aging, 2014 - Springer
Background Poor adherence may have a major impact on clinical outcome, contributing to
substantial worsening of disease, increased health care costs and even death. With …

[HTML][HTML] Adherencia terapéutica: factores modificadores y estrategias de mejora

MI Valverde-Merino - Ars Pharmaceutica (Internet), 2018 - SciELO Espana
Resumen PAGES-PUIGDEMONT, Neus y VALVERDE-MERINO, M. Isabel. Adherencia
terapéutica: factores modificadores y estrategias de mejora. Ars Pharm [online]. 2018, vol …